Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Other Non-Current Assets for 5 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 9.62% year-over-year to $11.3 million, compared with a TTM value of $11.3 million through Dec 2025, up 9.62%, and an annual FY2025 reading of $11.3 million, up 9.62% over the prior year.
  • Other Non-Current Assets was $11.3 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $8.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $11.3 million in Q4 2025 and bottomed at $827000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $6.2 million, with a median of $5.9 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets plummeted 85.8% in 2023, then skyrocketed 1147.28% in 2024.
  • Year by year, Other Non-Current Assets stood at $8.7 million in 2021, then plummeted by 33.21% to $5.8 million in 2022, then tumbled by 85.8% to $827000.0 in 2023, then surged by 1147.28% to $10.3 million in 2024, then rose by 9.62% to $11.3 million in 2025.
  • Business Quant data shows Other Non-Current Assets for KNSA at $11.3 million in Q4 2025, $8.3 million in Q3 2025, and $8.2 million in Q2 2025.